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Abstract
Background:  Invitrogen Gateway technology exploits the integrase/att  site-specific
recombination system for directional cloning of PCR products and the subsequent subcloning into
destination vectors. One or three DNA segments can be cloned using Gateway or MultiSite
Gateway respectively. A vast number of single-site Gateway destination vectors have been created
while MultiSite Gateway is limited to few destination vectors and therefore to few applications. The
aim of this work was to make the MultiSite Gateway technology available for multiple biological
purposes.
Results:  We created a construct, pDONR-R4-R3, to easily convert any available Gateway
destination vector to a MultiSite Gateway vector in a single recombination reaction. In addition, we
designed pDONR-R4-R3 so that DNA fragments already cloned upstream or downstream of the
Gateway cassette in the original destination vectors can still be utilized for promoter-gene or
translational fusions after the conversion.
Conclusion: Our tool makes MultiSite Gateway a more widely accessible technology and expands
its applications by exploiting all the features of the Gateway vectors already available.
Background
Recombinase-based cloning technologies are becoming
increasingly popular because of their easy use and high
efficiency. These tools exploit bacterial or viral site-specific
recombinases like the bacteriophage P1 Cre, the Saccharo-
myces cerevisiae FLP or the bacteriophage lambda integrase
[1-3]. These enzymes catalyze a reciprocal double-
stranded DNA exchange between two specific DNA sites
[4].
Gateway (Invitrogen) is one of the most popular recombi-
nation cloning technologies [3]. It is based on the
Escherichia coli bacteriophage lambda integrase/att system
[5]. Two sets of reactions are employed in this technology:
LR and BP recombinations (Fig 1). The BP reaction is cat-
alyzed by the BP Clonase enzyme mix (Invitrogen), which
recombines attB sites with attP sites. The LR Clonase mix
(Invitrogen) is responsible for recombination of attL sites
with attR sites. Any DNA fragment of interest can be PCR
amplified with primers containing attB sites and cloned
into a donor vector carrying attP sites in the presence of
the BP Clonase mix. The recombination of attB with attP
sites leads to the formation of attL and attR sites. The reac-
tion creates an entry clone bearing the insert of interest
flanked by attL sites and a byproduct flanked by attR sites
(Fig 1A). The insert can then be mobilized into any desti-
nation vector having attR sites via an LR reaction (Fig 1B).
The resulting construct can be easily selected using a com-
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bination of a positive (antibiotic resistance) and a nega-
tive (the cytotoxic ccdB gene) selection which does not
allow the growth of E. coli transformed with either the ini-
tial vectors or the by-product [3,6]. The vast number of
Gateway destination vectors designed for many different
biological analyses and the large collections of entry
clones carrying entire genome open reading frames make
this technology highly attractive.
A variant of Gateway, named MultiSite Gateway (Invitro-
gen), has been developed to facilitate the cloning of mul-
tiple DNA fragments [7]. By using four different attB sites
(attB1,  attB2,  attB3, and attB4), three PCR products
flanked by specific attB sites can be cloned into three
donor vectors bearing the corresponding attP sites (Fig
2A). The LR Clonase Plus mix (Invitrogen) specifically
recombines all attL sites with their corresponding attR
sites. A single LR Plus reaction with the three entry clones
and the pDEST-R4-R3 destination vector (Invitrogen) cre-
ates a construct with the three inserts in a defined and ori-
ented order (Fig 2B). Any Gateway entry clone can be
mobilized into a MultiSite Gateway destination vector.
Compared to Gateway, MultiSite Gateway is limited by
the availability of a small number of destination vectors
which prevents this powerful technology from being used
for multiple biological purposes.
Here we present a method to convert any Gateway vector
to a MultiSite Gateway vector via a single recombination
event.
Results and discussion
We decided to take advantage of the large number of Gate-
way single-site destination vectors and developed a new
method to easily convert them to MultiSite Gateway. The
functional part of MultiSite Gateway destination vectors is
the attR4-attR3 cassette which can recombine with three
Gateway donor vectors carrying the appropriate attL sites
(Fig 2B) [7]. We constructed a vector, pDONR-R4-R3, to
mobilize the attR4-attR3 cassette into any Gateway Desti-
nation vector. To create pDONR-R4-R3, we cloned a Gate-
way cassette inside another Gateway cassette by choosing
a combination of att sites that cannot recombine with one
another. We exploited the ability of the BP Clonase
enzyme mix to recombine attB sites with attP sites while
leaving attR sites untouched [3]. The attR4-attR3 cassette
Gateway BP and LR reactions Figure 1
Gateway BP and LR reactions. (A) BP recombination of a PCR product "X" flanked by attB sites with a Gateway donor 
vector [3]. (B) LR recombination of an entry clone bearing a DNA fragment "X" with a Gateway destination vector [3].BMC Molecular Biology 2006, 7:46 http://www.biomedcentral.com/1471-2199/7/46
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was amplified using attB primers and cloned into
pDONR221 (Invitrogen), a vector carrying an attP1-attP2
cassette. The BP recombination created the pDONR-R4-
R3 vector that contains the attR4-attR3 cassette flanked by
attL1-attL2 sites (Fig 3).
In order to use pDONR-R4-R3 to deliver the attR4-attR3
cassette into any Gateway destination vector in a single LR
reaction, we took advantage of the fact that attR4 and
attR3 sites cannot recombine with the flanking attL1 and
attL2 sites (Fig 2B) [7]. To test it, we performed LR reac-
MultiSite Gateway Figure 2
MultiSite Gateway. (A) BP recombinations of three PCR products "A", "B" and "C" flanked by attB sites with three Gateway 
donor vectors [7]. (B) LR plus recombination of three entry clones bearing the DNA fragments "A", "B" and "C" with the Mul-
tiSite Gateway destination vector pDEST-R4-R3 (Invitrogen) [7].BMC Molecular Biology 2006, 7:46 http://www.biomedcentral.com/1471-2199/7/46
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tions with pDONR-R4-R3 and three different Gateway
vectors: pDEST32 (Invitrogen), pDEST22 (Invitrogen)
and pMDC163 [8]. These specific destination vectors were
chosen to demonstrate the feasibility of the experiment.
The linearization of pDEST32 and pDEST22 inside the
Gateway cassette and their antibiotic resistance allowed us
to specifically select for and recover the entry clones
pDEST32-R4-R3 and pDEST22-R4-R3 bearing the attR4-
attR3 cassette flanked by attB1-attB2 sites (Fig 4A). Some
destination vectors, like pMDC163, carry the Kanamycin
resistance gene in discordance with the Invitrogen recom-
mendations. In this case, the linearization of the entry
clone efficiently works as a negative selector against the
non-recombined entry clone. The linearization of
pDONR-R4-R3 in the vector backbone and pMDC163
inside the Gateway cassette allowed us to specifically
recover pMDC163-R4-R3 (data not shown). The large
number of Gateway vectors already available for various
biological experiments can be easily converted to Multi-
Site Gateway vectors after an LR recombination with
pDONR-R4-R3.
Last, we performed an LR Plus reaction with pDEST22-R4-
R3 and pDEST32-R4-R3 to test the functionality of the
attR4-attR3 cassette flanked by attB1-attB2 sites (Fig 4B).
We used three entry clones bearing a 3434 bp, 3116 bp
and 561 bp DNA fragment cloned into pDONR-P4-P1R
(Invitrogen), pDONR221 and pDONR-P2R-P3 (Invitro-
gen) respectively [7]. Two LR Plus reactions were per-
formed with the entry clones and either pDEST22-R4-R3
pDONR-R4-R3 Figure 3
pDONR-R4-R3. BP recombination of the attR4-attR3 Gateway cassette flanked by attB1 and attB2 sites with a linear Gateway 
donor vector pDONR221 (Invitrogen) which leads to the creation of the vector pDONR-R4-R3 and a cytotoxic by-product.BMC Molecular Biology 2006, 7:46 http://www.biomedcentral.com/1471-2199/7/46
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or pDEST32-R4-R3. Both reactions led to the creation of
pDEST22 and pDEST32 expression clones containing the
inserts in the expected order (Fig 4B). Correct functioning
of the technology was further tested by cloning a different
set of three entry clones into pDEST22-R4-R3 (data not
shown). When the converted MultiSite Gateway destina-
tion vector bears a kanamycin resistance gene, like
pMDC163-R4-R3, the entry clones need to be linearized
in order to specifically recover the expression clone.
Figure 4C shows the external attB1-attB4 and attB3-attB2
sites of a converted MultiSite Gateway expression clone
which maintain the Gateway frame and lack start and stop
codons to allow promoter-gene or translational fusions.
Thus, converted MultiSite Gateway vectors can take
advantage of all reporter genes, tags or promoter
sequences already present in the original Gateway destina-
tion vectors.
Conclusion
We have developed a new method to convert virtually all
Gateway vectors to MultiSite Gateway. A careful combina-
tion of compatible att sites allowed us to use the Gateway
recombination technology to deliver a MultiSite Gateway
cassette. This strategy opens a new way of thinking about
recombination sites as cloning and clonable elements at
the same time and could apply to other recombination
cassettes. Our method makes the Invitrogen technology
Conversion of any Gateway destination vector to a MultiSite Gateway destination vector Figure 4
Conversion of any Gateway destination vector to a MultiSite Gateway destination vector. (A) LR recombination 
of the pDONR-R4-R3 vector with a linear Gateway destination vector. We tested this reaction using pDEST32 (Invitrogen) 
and pDEST22 (Invitrogen) destination vectors. (B) LR Plus recombination of three entry clones bearing the DNA fragments 
"A", "B" and "C" with a converted MultiSite Gateway destination vector. We tested this reaction by recombining three entry 
clones carrying a 3434 bp, 3116 bp and 561 bp DNA fragment with pDEST32-R4-R3 and pDEST22-R4-R3. (C) DNA and amino 
acid sequence of the external borders of the expression clone.BMC Molecular Biology 2006, 7:46 http://www.biomedcentral.com/1471-2199/7/46
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available to many biological systems for translational
fusion of different proteins or tags, expression of genes or
reporter genes under the control of specific promoters and
3'-UTRs, and combinatorial analysis of promoters, genes
or other DNA fragments. Our improvement also expands
the potential use of this recombination system by utiliz-
ing all the features of the large number of Gateway vectors
already created.
Methods
Construction of pDONR-R4-R3
We PCR amplified the attR4-attR3 cassette from the
pDEST-R4-R3 vector (Invitrogen) using the primers attB1-
attR4-F
(5'GGGGACAAGTTTGTACAAAAAAGCAGGCTCAACTTT
GTATAGAAAAGTTGAAC3') and attB2-attR3-R
(5'GGGGACCACTTTGTACAAGAAAGCTGGGTCAACTAT
GTATAATAAAGTTGAAC3'). We digested the pDONR221
vector (Invitrogen) with EcoRI and used it in a BP recom-
bination reaction (Invitrogen) according to the manufac-
turer with the attR4-attR3 cassette PCR fragment. We used
the reaction to transform DB3.1 E. coli cells (Invitrogen)
and selected them for kanamycin resistance. We named
the resultant vector pDONR-R4-R3.
Construction of pDEST22-R4-R3, pDEST32-R4-R3 and 
pMDC163-R4-R3
We digested the pDEST22 (Invitrogen), pDEST32 (Invit-
rogen) and pMDC163 [8] vectors with EcoRI, XbaI and
NcoI respectively. We conducted two independent LR
reactions (Invitrogen) according to the manufacturer
combining pDONR-R4-R3 with digested pDEST22 and
pDEST32. An additional LR reaction was performed com-
bining EcoNI linearized pDONR-R4-R3 with digested
pMDC163. We used the three reactions to transform
DB3.1 E. coli cells (Invitrogen) and selected them for amp-
icillin (pDEST22/pDONR-R4-R3 reaction), gentamicin
(pDEST32/pDONR-R4-R3 reaction) or kanamycin
(pMDC163/pDONR-R4-R3 reaction) resistance. We
named the resultant vectors pDEST22-R4-R3, pDEST32-
R4-R3 and pMDC163-R4-R3 respectively.
Construction of pDONR-P4-P1R-pPNY, pDONR221-PNY 
and pDONR-P2R-P3-YC
We PCR amplified 3434 bp upstream the start codon of
the Arabidopsis thaliana PENNYWISE  (PNY) gene [9]
using pny-attB4F (GGGGACAACTTTGTATAGAAAAGTT-
GTTGGCACGATTCTGAAACACG) and pny-attB1R
(GGGGACTGCTTTTTTGTACAAACTTGGGGAAAGGAT-
GATGTCGATGAG) primers, the PNY  gene (3116 bp)
using pny-attB1F (GGGACAAGTTTGTACAAAAAAGCAG-
GCTTGATGGCTGATGCATACGAGCC) and pny-attB2R
(GGGGACCACTTTGTACAAGAAAGCTGGGTAACCTA-
CAAAATCATGTAGAA) primers and a 561 bp fragment of
the pUC-SPYCE vector [10] using attB2-SPYCE-F
(GGGGACAGCTTTCTTGTACAAAGTGGGGATGTAC-
CCATACGATGTTCCA) and attB3-SPY-R
(GGGGACAACTTTGTATAATAAAGTTGGAATTC-
CCGATCTAGTAACATAGATG) primers. The PNY  pro-
moter region, the PNY  gene and pUC-SPYCE PCR
fragments were cloned into the pDONR-P4-P1R (Invitro-
gen), pDONR221 and pDONR-P2R-P3 (Invitrogen) vec-
tors respectively via three independent BP reactions
according to the manufacturer. We used the reactions to
transform TOP10 E. coli cells (Invitrogen) and selected
them for kanamycin resistance. We named the resultant
vectors pDONR-P4-P1R-pPNY, pDONR221-PNY and
pDONR-P2R-P3-YC respectively.
Construction of pDEST22-pPNY-PNY-YC and pDEST32-
pPNY-PNY-YC
We performed an LR Plus reaction (Invitrogen) according
to the manufacturer combining pDONR-P4-P1R-pPNY,
pDONR221-PNY, pDONR-P2R-P3-YC, and pDEST22-R4-
R3. We used the reaction to transform TOP10 E. coli cells
and selected for ampicillin resistance. We named the
resultant vectors pDEST22-pPNY-PNY-YC. We performed
another LR Plus reaction according to the manufacturer
combining pDONR-P4-P1R-pPNY, pDONR221-PNY,
pDONR-P2R-P3-YC, and pDEST32-R4-R3. We used the
reaction to transform TOP10 E. coli cells and selected for
gentamicin resistance. We named the resultant vectors
pDEST32-pPNY-PNY-YC.
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AMPr, ampicillin resistance.
CMR, chloramphenicol resistance.
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